ClinicalTrials.gg
CompletedNCT01896505Updated Jan 8, 2024Results posted

A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma

A Phase 1 interventional study of KCP-330 in Sarcoma, sponsored by Karyopharm Therapeutics Inc. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by Karyopharm Therapeutics Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
281st of 800
54 · median 35
Started
2013
with 21 others
Phase 1
281 of 958
36 open now
Registered
460th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 281st largest by enrollment of the 800 interventional ones that give a count, is one of 22 that started in 2013, is one of 281 in phase 1, and was the 460th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to find out more information such as: to determine the effects of high and low fat foods on the pharmacokinetics (PK) of oral KPT-330 tablets and to compare PK of capsules and tablets in Arms 1 and 2; to evaluate tumor response in sarcoma participants in Arm 3; to compare the PK of 60 milligrams (mg) of the new, 2nd generation tablet formulation and 60 mg of the selinexor suspension formula to the current, 1st generation tablets.

03

Conditions studied

  • Sarcoma

Keywords

  • Bone sarcoma
  • Soft-tissue sarcoma
  • Sarcoma
  • KPT-330
  • Food
  • Effects
  • Selinexor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed soft tissue or bone/cartilage sarcoma. Patients with sarcoma of small round blue cell tumor types are allowed. Gastrointestinal stromal tumors (GIST) are excluded.
  2. Patients must have received at least one prior anticancer regimen for disease unless there is no other therapy available and evidence of progressive disease on study entry. Patients with stable disease will be included if there has been failure to respond to another drug(s) within the previous 3 months

Exclusion criteria

Exclusion Criteria:

  1. Patients with known liver
  2. Radiation, chemotherapy, immunotherapy, any other systemic anticancer therapy or participation in an anti-cancer study ≤ 3 weeks prior to initiation of therapy
  3. Patients with known
  4. Patients with any gastrointestinal dysfunctions that could interfere with the interpretation of the food effect data
  5. Patients with known intolerance to low or high fat meals
  6. In the opinion of the investigator, patients who are significantly below their ideal body weight
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Arm 1

    Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 30 milligrams per meter square (mg/m\^2) orally twice weekly in treatment sequence ABCD (Treatment A: fasted, tablet formulation on Day 1 of Week 1; Treatment B: high-fat meal, tablet formulation on Day 1 of Week 2; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 3; Treatment D: low-fat meal, capsule formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).

    Drug: KCP-330

  • Experimental
    Arm 2

    Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received selinexor 30 mg/m\^2 orally twice weekly in treatment sequence BADC (Treatment B: high-fat meal, tablet formulation on Day 1 of Week 1; Treatment A: fasted, tablet formulation on Day 1 of Week 2; Treatment D: low fat meal, capsule formulation on Day 1 of Week 3; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.

    Drug: KCP-330

  • Experimental
    Arm 3

    Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 50 mg/m\^2 first generation tablets twice weekly on Days 1 and 3 of each week within 30 minutes of solid food consumption.

    Drug: KCP-330

  • Experimental
    Arm 4

    Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence ABC (Treatment A: current \[1st generation\] tablets on Day 1 of Week 1; Treatment B: new \[2nd generation\] tablets on Day 1 of Week 2; Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.

    Drug: KCP-330

  • Experimental
    Arm 5

    Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence CAB (Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 1; Treatment A: current \[1st generation\] tablets on Day 1 of Week 2; Treatment B: new \[2nd generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.

    Drug: KCP-330

  • Experimental
    Arm 6

    Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m\^2 orally in treatment sequence BCA (Treatment B: new \[2nd generation\] tablets on Day 1 of Week 1; Treatment C: suspension dose of current \[1st generation\] tablets on Day 1 of Week 2; Treatment A: current \[1st generation\] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.

    Drug: KCP-330

Interventions

  • Also known as: Selinexor

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor

    AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,18, 24, and 48 hours post-dose

  2. Area Under the Concentration Time Curve From the Time Zero to Extrapolated to Infinity (AUC0-inf) of Selinexor

    AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), AUC0-inf was calculated as AUC0-t + Ct/ elimination rate constant (kel), where: Ct = the last observed non- zero concentration.

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose

  3. Maximum Observed Plasma Concentration (Cmax) of Selinexor

    Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose

  4. Time of First Maximum Observed Concentration (Tmax) of Selinexor

    Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose

  5. Terminal Phase Half-Life (t1/2) of Selinexor

    t1/2 was the terminal phase half-life, it was calculated as ln(2)/kel.

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose

  6. Apparent Total Body Clearance (CL/F) of Selinexor

    Apparent total body clearance was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram \[kg\]).

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose

  7. Apparent Volume of Distribution (Vd/F) of Selinexor

    Vd/F was calculated as Dose/ (kel \*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kg).

    Time frame: Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Best Overall Response According to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Criteria

    Best overall response rate was defined as the percentage of participants who achieved complete response (CR), and partial response (PR), as assessed by the RECIST v1.1 criteria. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to less than (\<) 10 millimeter (mm). PR was defined as At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter (LD).

    Time frame: From the date of first documented response until the date of documented progression or last disease assessment (up to 39 months)

  2. Duration of Stable Disease as Per RECIST v1.1 Criteria

    Duration of at least stable disease was defined as the time from the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression as per RECIST v1.1 Criteria. Participants without evidence of progression were censored at time of last disease assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.

    Time frame: From the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression, censored date (up to 39 months)

  3. Progression Free Survival (PFS) as Per RECIST v1.1 Criteria

    PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST v1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions. Participants who were last known to be alive and without evidence of progression were censored at time of last disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, or 30 days after end of treatment, participants were censored at the time of last evaluable disease assessment prior to the missed assessment.

    Time frame: From first dose of study treatment to time of disease progression or death, censored date (up to 39 months)

  4. Overall Survival (OS)

    OS was defined as the time from date first dose of study treatment to the date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropped out prior to study end, were censored at the day they were last known to be alive.

    Time frame: From first dose of study treatment to death, censored date (up to 39 months)

  5. Time to Progression (TTP)

    TTP was defined as the time from date of first dose of study treatment to first documented evidence of disease recurrence or progression, or death due to disease progression, whichever occurred first. Participants without evidence of progression were censored at time of last evaluable disease assessment.

    Time frame: From first dose of study treatment to first documented evidence of disease recurrence or progression, or death, censored date (up to 39 months)

  6. Number of Participants With Growth Modulation Index (GMI) Less Than or Equal to (<=) 1.33 and Greater Than (>) 1.33

    GMI was defined as the ratio between the TTP with selinexor and the TTP with the most recent prior treatment. GMI was calculated, using a previously described threshold of 1.3 or greater as a sign of potential drug activity and improved overall survival.

    Time frame: Up to 39 months

  7. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a study and which does not necessarily have to have a causal relationship with this treatment. SAE defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) that and regardless of causality that: results in death, is life-threatening (participant was at immediate risk of death from event as it occurred), requires in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.

    Time frame: From screening up to 30 days post last study drug dose (up to 39 months)

  8. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

    AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur after participant's signed informed consent obtained. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 28 days following last dose or any event considered drug-related by the investigator through the end of the study. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death.

    Time frame: From screening up to 30 days post last study drug dose (up to 39 months)

  9. Number of Participants With Clinically Significant Laboratory Abnormalities

    Number of participants with clinically significant laboratory abnormalities including clinical chemistry, hematology, coagulation and urinalysis. Number of participants with clinically significant laboratory abnormalities which were deemed clinically significant by the investigator were reported.

    Time frame: From screening up to 30 days post last study drug dose (up to 39 months)

  10. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included blood pressure (systolic blood pressure and diastolic blood pressure). Measurements were made after the participant had been resting supine for a minimum of 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator occurring at any time on treatment from normal pre-dose based on the condition met (Yes/No). Number of participants with clinically significant changes in vital signs with condition (Yes) were only reported.

    Time frame: From screening up to 30 days post last study drug dose (up to 39 months)

  11. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)

    Twelve lead ECGs were obtained after the participant has rested in a supine position for at least 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator or designated physician occurring at any time on treatment from normal pre-dose.

    Time frame: From screening up to 30 days post last study drug dose

07

Results

Posted Jan 8, 2024

Participant flow

This study was conducted at 2 sites in United States and Canada from 30 July 2013 to 21 October 2016.

Participant flow — Overall Study
MilestoneArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
Started10917756
Completed000000
Not completed10917756
Withdrew: Adverse event102110
Withdrew: Physician decision132001
Withdrew: Withdrawal by subject103100
Withdrew: Disease progression758444
Withdrew: Need of treatment not allowed per protocol001000
Withdrew: Intercurrent illness010000
Withdrew: Death001101

Outcome measures

PrimaryArea Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor

AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,18, 24, and 48 hours post-dose
Reported as:
Geometric mean · Nanograms*hour per milliliter (ng*h/mL)
Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor
Nanograms*hour per milliliter (ng*h/mL)Arms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor2752 ± 37.53175 ± 25.33280 ± 19.33342 ± 21.44086 ± 22.34220 ± 22.03955 ± 21.2
PrimaryArea Under the Concentration Time Curve From the Time Zero to Extrapolated to Infinity (AUC0-inf) of Selinexor

AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), AUC0-inf was calculated as AUC0-t + Ct/ elimination rate constant (kel), where: Ct = the last observed non- zero concentration.

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From the Time Zero to Extrapolated to Infinity (AUC0-inf) of Selinexor
ng*h/mLArms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Area Under the Concentration Time Curve From the Time Zero to Extrapolated to Infinity (AUC0-inf) of Selinexor2969 ± 34.13412 ± 23.83483 ± 18.13561 ± 20.64117 ± 22.44250 ± 21.84002 ± 21.1
PrimaryMaximum Observed Plasma Concentration (Cmax) of Selinexor

Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Selinexor
Nanogram per milliliter (ng/mL)Arms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Maximum Observed Plasma Concentration (Cmax) of Selinexor355 ± 52.6404 ± 39.1436 ± 21.9429 ± 29.1519 ± 34.4527 ± 30.7450 ± 52.8
PrimaryTime of First Maximum Observed Concentration (Tmax) of Selinexor

Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Reported as:
Median · Hour
Time of First Maximum Observed Concentration (Tmax) of Selinexor
HourArms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Time of First Maximum Observed Concentration (Tmax) of Selinexor1.5 (1.0 to 6.1)3.4 (1.5 to 8.0)3.4 (1.4 to 6.1)3.8 (1.5 to 5.0)2.1 (0.6 to 5.1)3.0 (1.0 to 4.2)1.6 (1.0 to 9.7)
PrimaryTerminal Phase Half-Life (t1/2) of Selinexor

t1/2 was the terminal phase half-life, it was calculated as ln(2)/kel.

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Reported as:
Mean · Hour
Terminal Phase Half-Life (t1/2) of Selinexor
HourArms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Terminal Phase Half-Life (t1/2) of Selinexor6.2 ± 1.715.9 ± 1.365.6 ± 1.005.7 ± 1.066.7 ± 1.346.6 ± 1.146.5 ± 1.51
PrimaryApparent Total Body Clearance (CL/F) of Selinexor

Apparent total body clearance was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram \[kg\]).

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Reported as:
Geometric mean · Liter per hour per kilogram (L/h/kg)
Apparent Total Body Clearance (CL/F) of Selinexor
Liter per hour per kilogram (L/h/kg)Arms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Apparent Total Body Clearance (CL/F) of Selinexor0.3 ± 32.10.22 ± 21.30.22 ± 16.30.21 ± 18.70.21 ± 20.60.20 ± 16.60.21 ± 14.2
PrimaryApparent Volume of Distribution (Vd/F) of Selinexor

Vd/F was calculated as Dose/ (kel \*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kg).

Time frame:
Day 1 of weeks 1-3 in Cycle 1: Pre-dose (within 10 minutes before swallowing study drug), 15, 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 18, 24, and 48 hours post-dose
Reported as:
Geometric mean · Liter per kilogram (L/kg)
Apparent Volume of Distribution (Vd/F) of Selinexor
Liter per kilogram (L/kg)Arms 1 and 2: Treatment A: Fasted, Tablet FormulationArms 1 and 2: Treatment B: High-Fat Meal, Tablet FormulationArms 1 and 2: Treatment C: Low-Fat Meal, Tablet FormulationArms 1 and 2: Treatment D: Low-Fat Meal, Capsule FormulationArms 4, 5, and 6: Treatment A: First Generation TabletArms 4, 5, and 6: Treatment B: Second Generation TabletArms 4, 5, and 6: Treatment C: Oral Suspension
Apparent Volume of Distribution (Vd/F) of Selinexor2.2 ± 49.51.8 ± 32.31.7 ± 26.11.7 ± 26.62.0 ± 16.91.9 ± 18.31.9 ± 18.2
SecondaryPercentage of Participants With Best Overall Response According to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Criteria

Best overall response rate was defined as the percentage of participants who achieved complete response (CR), and partial response (PR), as assessed by the RECIST v1.1 criteria. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to less than (\<) 10 millimeter (mm). PR was defined as At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameter (LD).

Time frame:
From the date of first documented response until the date of documented progression or last disease assessment (up to 39 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response According to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Criteria
Percentage of participantsLiposarcomaLeiomyosarcomaOther Sarcoma
Complete Response (CR)000
Partial Response (PR)000
SecondaryDuration of Stable Disease as Per RECIST v1.1 Criteria

Duration of at least stable disease was defined as the time from the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression as per RECIST v1.1 Criteria. Participants without evidence of progression were censored at time of last disease assessment. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded since the treatment started. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Appearance of one or more new lesions also constituted progressive disease.

Time frame:
From the date of first dose of study treatment to first documented radiologic evidence of disease recurrence or progression, censored date (up to 39 months)
Reported as:
Median · Months
Duration of Stable Disease as Per RECIST v1.1 Criteria
MonthsLiposarcomaLeiomyosarcomaOther Sarcoma
Duration of Stable Disease as Per RECIST v1.1 Criteria7.49 (3.55 to NA)3.94 (1.64 to 5.55)8.34 (3.09 to NA)
SecondaryProgression Free Survival (PFS) as Per RECIST v1.1 Criteria

PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST v1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions. Participants who were last known to be alive and without evidence of progression were censored at time of last disease assessment. If date of progression or death occurred after more than 1 missed disease assessment interval, or 30 days after end of treatment, participants were censored at the time of last evaluable disease assessment prior to the missed assessment.

Time frame:
From first dose of study treatment to time of disease progression or death, censored date (up to 39 months)
Reported as:
Median · Months
Progression Free Survival (PFS) as Per RECIST v1.1 Criteria
MonthsLiposarcomaLeiomyosarcomaOther Sarcoma
Progression Free Survival (PFS) as Per RECIST v1.1 Criteria4.44 (2.07 to 7.49)3.52 (1.48 to 5.55)1.84 (1.02 to 3.58)
SecondaryOverall Survival (OS)

OS was defined as the time from date first dose of study treatment to the date of death. Participants who were still alive prior to the data cutoff for final efficacy analysis, or who dropped out prior to study end, were censored at the day they were last known to be alive.

Time frame:
From first dose of study treatment to death, censored date (up to 39 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsLiposarcomaLeiomyosarcomaOther Sarcoma
Overall Survival (OS)9.00 (4.76 to NA)7.03 (5.75 to NA)NA (3.38 to NA)
SecondaryTime to Progression (TTP)

TTP was defined as the time from date of first dose of study treatment to first documented evidence of disease recurrence or progression, or death due to disease progression, whichever occurred first. Participants without evidence of progression were censored at time of last evaluable disease assessment.

Time frame:
From first dose of study treatment to first documented evidence of disease recurrence or progression, or death, censored date (up to 39 months)
Reported as:
Median · Months
Time to Progression (TTP)
MonthsLiposarcomaLeiomyosarcomaOther Sarcoma
Time to Progression (TTP)4.44 (2.07 to NA)3.52 (1.48 to 5.55)1.74 (1.02 to 5.55)
SecondaryNumber of Participants With Growth Modulation Index (GMI) Less Than or Equal to (<=) 1.33 and Greater Than (>) 1.33

GMI was defined as the ratio between the TTP with selinexor and the TTP with the most recent prior treatment. GMI was calculated, using a previously described threshold of 1.3 or greater as a sign of potential drug activity and improved overall survival.

Time frame:
Up to 39 months
Reported as:
Count of participants · Participants
Number of Participants With Growth Modulation Index (GMI) Less Than or Equal to (<=) 1.33 and Greater Than (>) 1.33
ParticipantsLiposarcomaLeiomyosarcomaOther Sarcoma
GMI <= 1.3311817
GMI > 1.33743
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a study and which does not necessarily have to have a causal relationship with this treatment. SAE defined as any AE, occurring at any dose (including after the informed consent form was signed and prior to dosing) that and regardless of causality that: results in death, is life-threatening (participant was at immediate risk of death from event as it occurred), requires in-patient hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.

Time frame:
From screening up to 30 days post last study drug dose (up to 39 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
Participants with TEAEs10917756
Participants with Serious TEAEs455224
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur after participant's signed informed consent obtained. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study treatment through 28 days following last dose or any event considered drug-related by the investigator through the end of the study. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death.

Time frame:
From screening up to 30 days post last study drug dose (up to 39 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
ParticipantsArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
Grade 1: Mild000000
Grade 2: Moderate322111
Grade 3: Severe5514324
Grade 4: Life Threatening210311
Grade 5: Fatal011010
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities

Number of participants with clinically significant laboratory abnormalities including clinical chemistry, hematology, coagulation and urinalysis. Number of participants with clinically significant laboratory abnormalities which were deemed clinically significant by the investigator were reported.

Time frame:
From screening up to 30 days post last study drug dose (up to 39 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
Hematology127121
Clinical Chemistry417111
Coagulation: Prothrombin intl. normalized ratio001000
Urinalysis000000
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Vital signs included blood pressure (systolic blood pressure and diastolic blood pressure). Measurements were made after the participant had been resting supine for a minimum of 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator occurring at any time on treatment from normal pre-dose based on the condition met (Yes/No). Number of participants with clinically significant changes in vital signs with condition (Yes) were only reported.

Time frame:
From screening up to 30 days post last study drug dose (up to 39 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
Systolic Blood Pressure: < 100 mmHg (Yes)258433
Systolic Blood Pressure: > 10 mmHg decrease from baseline (Yes)3714655
Systolic Blood Pressure: > 20 mmHg decrease from baseline (Yes)2410413
Systolic Blood Pressure: < 100 mmHg and > 10 mmHg decrease from baseline (Yes)147332
Systolic Blood Pressure: < 100 mmHg and > 20 mmHg decrease from baseline (Yes)114212
Diastolic Blood Pressure: < 60 mmHg (Yes)2310222
Diastolic Blood Pressure: > 5 mmHg decrease from baseline (Yes)8715645
Diastolic Blood Pressure: > 10 mmHg decrease from baseline (Yes)5512534
Diastolic Blood Pressure: < 60 mmHg and > 5 mmHg decrease from baseline (Yes)229212
Diastolic Blood Pressure: < 60 mmHg and > 10 mmHg decrease from baseline (Yes)229202
Systolic Blood Pressure : > 140 mmHg (Yes)236233
Systolic Blood Pressure: > 160 mmHg (Yes)001100
Systolic Blood Pressure: > 10 mmHg increase from baseline (Yes)2611345
Systolic Blood Pressure: > 20 mmHg increase from baseline (Yes)153114
Systolic Blood Pressure: > 160 mmHg and > 10 mmHg increase from baseline (Yes)001100
Systolic Blood Pressure: > 160 mmHg and > 20 mmHg increase from baseline (Yes)000000
Diastolic Blood Pressure: > 90 mmHg (Yes)436233
Diastolic Blood Pressure: > 100 mmHg (Yes)001100
Diastolic Blood Pressure: > 5 mmHg increase from baseline (Yes)6513446
Diastolic Blood Pressure: > 10 mmHg increase from baseline (Yes)248234
Diastolic Blood Pressure: > 100 mmHg and > 5 mmHg increase from baseline (Yes)001100
Diastolic Blood Pressure: > 100 mmHg and > 10 mmHg increase from baseline (Yes)000100
SecondaryNumber of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)

Twelve lead ECGs were obtained after the participant has rested in a supine position for at least 5 minutes. Clinically significant findings were defined as such in the opinion of the investigator or designated physician occurring at any time on treatment from normal pre-dose.

Time frame:
From screening up to 30 days post last study drug dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)
ParticipantsArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)201000

Adverse events

Collected over From screening up to 30 days post last study drug dose (up to 39 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1:2/10 (20%)4/10 (40%)10/10 (100%)
Arm 2:2/9 (22.2%)5/9 (55.6%)9/9 (100%)
Arm 3:1/17 (5.9%)5/17 (29.4%)17/17 (100%)
Arm 4:3/7 (42.9%)2/7 (28.6%)7/7 (100%)
Arm 5:3/5 (60%)2/5 (40%)5/5 (100%)
Arm 6:2/6 (33.3%)4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
ThrombocytopeniaBlood and lymphatic system disorders0/101/90/170/71/50/6
DeathGeneral disorders0/101/90/170/71/50/6
SepsisInfections and infestations2/100/90/170/70/50/6
Lung infectionInfections and infestations0/100/90/170/71/50/6
FallInjury, poisoning and procedural complications0/100/90/170/71/50/6
AnaemiaBlood and lymphatic system disorders0/100/90/170/70/51/6
CataractEye disorders0/100/90/170/70/51/6
Small intestinal obstructionGastrointestinal disorders1/101/90/170/70/51/6
Wound complicationInjury, poisoning and procedural complications0/100/90/170/70/51/6
EmbolismVascular disorders1/100/90/170/70/51/6
Most frequent other events
Showing 10 of 214
Most frequent other events
EventArm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:
ThrombocytopeniaBlood and lymphatic system disorders2/108/99/171/75/53/6
NauseaGastrointestinal disorders7/108/917/176/74/55/6
FatigueGeneral disorders8/109/916/174/75/56/6
AnaemiaBlood and lymphatic system disorders3/107/912/171/74/55/6
ConstipationGastrointestinal disorders5/105/912/173/72/55/6
LeukopeniaBlood and lymphatic system disorders2/107/96/170/72/53/6
VomitingGastrointestinal disorders5/105/912/174/73/53/6
DysgeusiaNervous system disorders3/105/98/170/71/54/6
DizzinessNervous system disorders2/103/911/171/72/51/6
DiarrhoeaGastrointestinal disorders6/104/95/171/71/53/6

Baseline characteristics

Safety population consisted of all participants who received at least one dose of selinexor.

Age, Continuous
Age, Continuous(Years)Arm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:Total
Mean51.7 ± 12.7257.6 ± 17.1859.9 ± 13.9053.4 ± 8.1043.6 ± 19.3253.8 ± 11.6255.0 ± 14.22
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:Total
Female471133331
Male62642323
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:Total
Hispanic or Latino0000000
Not Hispanic or Latino971674649
Unknown or Not Reported1210105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1:Arm 2:Arm 3:Arm 4:Arm 5:Arm 6:Total
American Indian or Alaska Native0000000
Asian1022117
Native Hawaiian or Other Pacific Islander0000000
Black or African American0011103
White891243541
Unknown or Not Reported1010002
Other0010001
08

Study locations

2 sites
  • Memorial Sloan Kettering Cancer Centre
    New York, New York 10065, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5T 2M9, Canada
09

References and documents

Publications

  • Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. Erratum In: J Clin Oncol. 2017 Mar;35(7):812. doi: 10.1200/JCO.2016.72.5226. PubMed 27458288 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Oct 2016, 38 months.

Results were first posted in Jan 2024, 7 years 2 months after primary completion.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's 38 months is below that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2013
First posted
Jul 11, 2013
StartActual
Jul 30, 2013
Primary completionActual
Oct 21, 2016
CompletionActual
Oct 21, 2016
Results first posted
Jan 8, 2024
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01896505
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Jul 30, 2013
Primary completion
Oct 21, 2016
Completion
Oct 21, 2016
Results posted
Jan 8, 2024
Last update
Jan 8, 2024

Study contacts

Michael Kauffman, MD, Ph.D
study director · Karyopharm Therapeutics Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion